ATE288764T1 - Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigen - Google Patents
Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigenInfo
- Publication number
- ATE288764T1 ATE288764T1 AT97936334T AT97936334T ATE288764T1 AT E288764 T1 ATE288764 T1 AT E288764T1 AT 97936334 T AT97936334 T AT 97936334T AT 97936334 T AT97936334 T AT 97936334T AT E288764 T1 ATE288764 T1 AT E288764T1
- Authority
- AT
- Austria
- Prior art keywords
- mhc class
- class
- heavy chains
- human cytomegalovirus
- expression
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000001514 detection method Methods 0.000 title 1
- 108091054437 MHC class I family Proteins 0.000 abstract 3
- 102000043129 MHC class I family Human genes 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000030741 antigen processing and presentation Effects 0.000 abstract 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000010189 intracellular transport Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 230000001960 triggered effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2284796P | 1996-07-31 | 1996-07-31 | |
| US4621397P | 1997-05-12 | 1997-05-12 | |
| PCT/US1997/013509 WO1998004285A1 (en) | 1996-07-31 | 1997-07-31 | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE288764T1 true ATE288764T1 (de) | 2005-02-15 |
Family
ID=26696435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97936334T ATE288764T1 (de) | 1996-07-31 | 1997-07-31 | Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6033671A (de) |
| EP (1) | EP0966301B1 (de) |
| AT (1) | ATE288764T1 (de) |
| AU (1) | AU730351B2 (de) |
| DE (1) | DE69732498T2 (de) |
| ES (1) | ES2237800T3 (de) |
| PT (1) | PT966301E (de) |
| WO (1) | WO1998004285A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998047914A2 (de) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gen aus dem humanen cytomegalovirus (hcmv) |
| AU2002242085A1 (en) | 2001-02-02 | 2002-08-19 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| EP2140879A1 (de) * | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Zusammensetzung und Verfahren zur Behandlung von Krebs mithilfe des Herpesvirus |
| CA2793959C (en) * | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| US20120020885A1 (en) * | 2010-07-26 | 2012-01-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | MHC-Less cells |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| AU2014225886B2 (en) | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| SG11201706454VA (en) | 2015-02-10 | 2017-09-28 | Univ Oregon Health & Science | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| EP3474889A4 (de) | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | Rekombinante cytomegalovirus-vektoren als impfstoffe gegen tuberkulose |
| BR112019007982A2 (pt) | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
| WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | CASSETTES OF ANTIGENS OF TUBERCULOSIS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877004A (en) * | 1991-07-05 | 1999-03-02 | American Cyanamid Compound | Human cytomegalovirus containing a β-glucuronidase marker gene |
| US5846806A (en) * | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| WO1998047914A2 (de) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gen aus dem humanen cytomegalovirus (hcmv) |
-
1997
- 1997-07-31 EP EP19970936334 patent/EP0966301B1/de not_active Expired - Lifetime
- 1997-07-31 ES ES97936334T patent/ES2237800T3/es not_active Expired - Lifetime
- 1997-07-31 US US08/903,805 patent/US6033671A/en not_active Expired - Lifetime
- 1997-07-31 AU AU39032/97A patent/AU730351B2/en not_active Expired
- 1997-07-31 PT PT97936334T patent/PT966301E/pt unknown
- 1997-07-31 WO PCT/US1997/013509 patent/WO1998004285A1/en not_active Ceased
- 1997-07-31 DE DE1997632498 patent/DE69732498T2/de not_active Expired - Lifetime
- 1997-07-31 AT AT97936334T patent/ATE288764T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0966301A1 (de) | 1999-12-29 |
| DE69732498D1 (de) | 2005-03-17 |
| PT966301E (pt) | 2005-06-30 |
| EP0966301A4 (de) | 2001-09-05 |
| US6033671A (en) | 2000-03-07 |
| AU3903297A (en) | 1998-02-20 |
| ES2237800T3 (es) | 2005-08-01 |
| EP0966301B1 (de) | 2005-02-09 |
| AU730351B2 (en) | 2001-03-08 |
| WO1998004285A1 (en) | 1998-02-05 |
| DE69732498T2 (de) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE288764T1 (de) | Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigen | |
| Bonneville et al. | Intestinal intraepithelial lymphocytes are a distinct set of γδ T cells | |
| Braud et al. | Functions of nonclassical MHC and non-MHC-encoded class I molecules | |
| Pien et al. | Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors | |
| Acha-Orbea et al. | Clonal deletion of V β 814-bearing T cells in mice transgenic for mammary tumour virus | |
| Dill et al. | Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice. | |
| US6361770B1 (en) | Method of enhancing expression of MHC class I molecules bearing endogenous peptides | |
| Serna et al. | Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells | |
| NZ530583A (en) | Novel B7-4 molecules and uses therefor | |
| WO2003102023A1 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| Pettigrew et al. | Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts | |
| Miller et al. | CD94/NKG2 expression does not inhibit cytotoxic function of lymphocytic choriomeningitis virus-specific CD8+ T cells | |
| Hölzemer et al. | Natural killer cell interactions with classical and non-classical human leukocyte antigen class I in HIV-1 infection | |
| Daha et al. | The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro | |
| Pangburn | Spontaneous thioester bond formation in α2-macroglobulin, C3 and C4 | |
| Elliott et al. | Short peptides assist the folding of free class I heavy chains in solution | |
| Sarmiento et al. | Cell surface polypeptides of murine T-cell clones expressing cytolytic or amplifier activity. | |
| US10736933B2 (en) | Peptide-induced NK cell activation | |
| Busch et al. | MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies—a tool for decreased immunogenicity of allogeneic tissue and cell transplants | |
| US10995116B2 (en) | Peptide-induced NK cell activation | |
| Saulquin et al. | Frequent recognition of BCRF1, a late lytic cycle protein of Epstein‐Barr virus, in the HLA‐B* 2705 context: evidence for a TAP‐independent processing | |
| Ding et al. | Direct Binding of Purified HLA Class I Antigens by Soluble NKG2/CD94 C‐Type Lectins from Natural Killer Cells | |
| Cairo et al. | The Vγ2/Vδ2 T‐cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vγ2/Jγ1. 2 subset | |
| KR100201584B1 (ko) | 사람 파필로마 바이러스 18형 이6 단백질에 대한 인체의 면역성 조절 기능을 갖는 펩타이드 | |
| Ferguson et al. | Localization of the disulfide bridges of human histocompatibility antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0966301 Country of ref document: EP |